A Study of Different Heart Imaging Techniques to Detect Amyloidosis Involving the Heart

Overview

About this study

The purpose of this study is to evaluate different heart imaging techniques to detect amyloidosis involving the heart. We are doing this research study to characterize the differences between types of amyloid and other diseases that mimic the appearance of amyloid involving the heart by using several imaging studies.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Patient is ≥ 40 years-old.
  2. If female, patient is post-menopausal or negative pregnancy (blood or urine) test through Mayo laboratory prior to nuclear imaging study.

AL-CM Arm:

  1. Patient has documented AL-CM defined as:
    1. Presence of amyloid in cardiac biopsy tissue (as determined by congo red stain or sulfated alcin blue stain), or
    2. Evidence of cardiac amyloid involvement by echocardiography and presence of amyloid in non-cardiac biopsy tissue
    3. High clinical suspicion of AL amyloid and subtyping by mass spectrometry ordered for confirmation

ATTR-CM Arm:

  1. Variant TTR amyloid cardiomyopathy as defined as:
    1. Known amyloid-associated genotype by direct sequencing of entire TTR gene and presence of amyloid in cardiac biopsy tissue (as determined by congo red stain, alcin blue stain, or mass spec analysis), or
  2. Variant TTR amyloid cardiomyopathy as defined as:
    1. Known amyloid-associated genotype by direct sequencing of entire TTR gene, evidence of cardiac involvement by echocardiography with left ventricle wall thickness > 12 mm and presence of amyloid in non-cardiac biopsy tissue (as determined by congo red stain, alcin blue stain, or mass spec analysis), or
  3. Wild-type TTR amyloid cardiomyopathy as defined as:
    1. Normal TTR genotype and presence of TTR amyloid deposits in cardiac biopsy tissue (as determined by congo red stain and mass spec analysis), or
  4. Wild-type TTR amyloid cardiomyopathy as defined as:
    1. Normal TTR genotype, evidence of cardiac involvement by echocardiography with left ventricle wall thickness > 12 mm and presence of TTR amyloid deposits in non-cardiac biopsy tissue (as determined by congo red stain and mass spec analysis).

Non-amyloid Control Arm:

  1. No clinical or laboratory evidence of amyloid.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

J. Wells Askew, M.D.

Closed for enrollment

Contact information:

Kera Delaney CCRP

(507)293-5660

Delaney.Kera@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20317347

Mayo Clinic Footer